MTNB Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1582554 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY58.9%
TTM EPS YoY114.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-147.5%
ROA-98.4%
ROIC (approx.)-535.3%
Asset turnover—
Leverage & solvency
Liabilities / assets33.1%
Debt / equity0.00x
Current ratio1.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $1.10M | $3.19M | $33,000 |
| R&D expense | $85,000 | $11.43M | $14.49M | $16.68M | $14.58M |
| SG&A expense | $6.88M | $8.73M | $10.37M | $11.10M | $10.19M |
| Operating income | -$6.96M | -$24.59M | -$23.77M | -$24.59M | -$24.73M |
| Pretax income | -$10.35M | -$24.33M | -$22.94M | — | — |
| Income tax | — | -$80,000 | — | — | — |
| Net income | -$10.35M | -$24.25M | -$22.94M | -$21.00M | -$23.28M |
| EBITDA | -$6.93M | -$24.23M | -$23.38M | -$24.25M | -$24.49M |
| EPS (basic) | -2.00 | -4.98 | -5.28 | -0.10 | -0.11 |
| EPS (diluted) | -2.00 | -4.98 | -5.28 | -0.10 | -0.11 |
| Weighted avg. shares (diluted) | 5.47M | 4.87M | 4.35M | 216.81M | 210.18M |
| Balance sheet | |||||
| Cash & equivalents | $4.00M | $7.28M | $4.79M | $6.83M | $21.03M |
| Short-term investments | — | — | $8.97M | $21.93M | $28.59M |
| Current assets | $4.08M | $8.03M | $15.54M | $34.53M | $50.99M |
| PP&E, net | $138,000 | $468,000 | $1.92M | $2.09M | $1.54M |
| Goodwill | — | — | $1.34M | $1.34M | $1.34M |
| Intangibles | $2.26M | $2.26M | $3.02M | $3.02M | $3.02M |
| Total assets | $7.21M | $12.64M | $25.10M | $44.82M | $61.33M |
| Current liabilities | $1.46M | $2.67M | $2.62M | $4.29M | $4.35M |
| Total liabilities | $2.38M | $5.05M | $5.86M | $8.18M | $8.83M |
| Shareholders' equity | $4.83M | $7.59M | $19.25M | $36.64M | $52.49M |
| Shares outstanding | 427,079 | 5.09M | 4.35M | 217.26M | 216.27M |
| Cash flow statement | |||||
| Operating cash flow | -$7.01M | -$15.88M | -$15.28M | -$19.16M | -$15.22M |
| Capital expenditure | — | — | $218,000 | $892,000 | $260,000 |
| Free cash flow | — | — | -$15.50M | -$20.05M | -$15.48M |
| Investing cash flow | $335,000 | $9.21M | $13.24M | $4.88M | $16.77M |
| Financing cash flow | $3.39M | $9.17M | -$7,000 | $79,000 | $6.96M |
| Depreciation & amortization | $32,000 | $365,000 | $385,000 | $337,000 | $244,000 |
| Stock-based compensation | $1.02M | $3.19M | $4.95M | $5.23M | $4.29M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.